The document calls for papers for a special issue of the Canadian Respiratory Journal on advanced monoclonal antibodies for asthma. It discusses how monoclonal antibodies work in treating asthma by altering inflammatory proteins and redox metabolites. It invites original research and review articles on targeted therapeutics for severe asthma using monoclonal antibodies against IL5, IL17, VCAM1, mepolizumab, reslizumab, and IL13. Potential topics also include real-life data and effects on comorbidities of monoclonal antibody therapy in asthma patients.